Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Alessio Giuseppe Morganti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9793-3410; OpenAlex author ID A5038579623. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 25

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PA… Last author DOI 10.3390/curroncol30060427↗
  3. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. Co-author DOI 10.1159/000525945↗
  4. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review. Last author DOI 10.3390/curroncol29040214↗
  5. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03411-7↗
  6. Correction to: Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03439-9↗
  7. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.07.052↗
  8. Definition of Local Recurrence Site in Resected Pancreatic Adenocarcinoma: A Multicenter Study (DOLORES-1). Co-author DOI 10.3390/cancers13123051↗
  9. Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer. Last author DOI 10.1002/acm2.13025↗
  10. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Last author DOI 10.1002/cam4.3330↗
  11. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Co-author DOI 10.21873/anticanres.13975↗
  12. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical … Last author DOI 10.3390/cancers12071729↗
  13. Radiotherapy of pancreatic cancer in older patients: A systematic review. Last author DOI 10.1016/j.jgo.2018.09.007↗
  14. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. First author DOI 10.1016/j.tranon.2018.08.017↗
  15. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a m… Co-author DOI 10.1080/0284186x.2018.1546899↗
  16. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  17. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. Last author DOI 10.2147/jpr.s167994↗
  18. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  19. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗
  20. Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. Co-author DOI 10.3892/or.2015.3955↗
  21. Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. Last author PMID 26026108↗
  22. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2014.07.024↗
  23. Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience. Co-author DOI 10.1186/1748-717x-9-198↗
  24. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2767-7↗
  25. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Last author DOI 10.1186/1748-717x-7-86↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriella Macchia · 18 shared papers, 2012–2023 · strength 1.52
  2. Francesco Cellini · 15 shared papers, 2016–2023 · strength 1.39
  3. Milly Buwenge · 13 shared papers, 2018–2023 · strength 1.30
  4. Vincenzo Valentini · 16 shared papers, 2012–2022 · strength 1.17
  5. Gian Carlo Mattiucci · 14 shared papers, 2013–2023 · strength 1.06
  6. Alessandra Arcelli · 10 shared papers, 2018–2023 · strength 0.95
  7. Savino Cilla · 9 shared papers, 2012–2023 · strength 0.84
  8. S. Cammelli · 7 shared papers, 2018–2022 · strength 0.68
  9. Nicola Simoni · 5 shared papers, 2019–2023 · strength 0.47
  10. Renzo Mazzarotto · 4 shared papers, 2020–2023 · strength 0.40
  11. Domenico Genovesi · 6 shared papers, 2014–2021 · strength 0.38
  12. Lidia Strigari · 3 shared papers, 2021–2023 · strength 0.38
  13. Mariacristina Di Marco · 4 shared papers, 2019–2023 · strength 0.37
  14. Sergio Alfieri · 6 shared papers, 2013–2022 · strength 0.37
  15. Michele Fiore · 4 shared papers, 2015–2023 · strength 0.35
  16. Massimo Falconi · 6 shared papers, 2014–2019 · strength 0.31
  17. Michele Reni · 6 shared papers, 2014–2019 · strength 0.31
  18. Luciana Caravatta · 5 shared papers, 2012–2020 · strength 0.27
  19. A. Sainato · 4 shared papers, 2014–2021 · strength 0.24
  20. Luca Boldrini · 2 shared papers, 2021 · strength 0.24
  21. Riccardo Casadei · 3 shared papers, 2019–2020 · strength 0.22
  22. Lorenzo Fuccio · 3 shared papers, 2018–2019 · strength 0.21
  23. Stefano Partelli · 4 shared papers, 2015–2019 · strength 0.21
  24. William F. Regine · 4 shared papers, 2014–2019 · strength 0.21
  25. Felipe Ángel Calvo · 4 shared papers, 2014–2019 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.